Genedrive Share Discussion Threads

[craffert] 02/2/2021 16:24

The interesting aspect of these guys vs AVCT/NCYT is the distribution relationship with Beckman Coulter. I think it's pretty much inevitable that Beckman will buy them as soon as they start to get feedback from their US and European sales squads. Why would Beckman bother buying hundreds of million from little Genedrive when they could make a cheeky £2.50 offer in the next couple of months before the volume surges. But today the shares seem like a steal at anything under £2 given the commencement of sales and the huge scale of Beckman to put product in the market as fast as GDR can make it.

[hazl] 02/2/2021 16:24

Expect there's quite a few waiting in the wings bunz3.

[bunz3] 02/2/2021 16:18

will Tomorrow morning see more of a move up again

[richardp19] 02/2/2021 16:16

I got a good feeling other news is incoming

[bunz3] 02/2/2021 16:07

with how low the supply of available shares lookes to be Today with how much nt being quoted

how much this moving up with volume ,next week if more people who have read last weeks rns wanting in before Mid February ,how much is this likely to move up
find this part of last weeks rns interesting




The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.



David Budd, CEO of genedrive plc, said: "We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority. The combination of genedrive and Beckman Coulter products and expertise provides the Company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously.



"We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products."



The Companies are planning commercial introduction of the Genedrive kit from mid February, following commercial and technical training of the Beckman sale and support organisations.

[losses] 02/2/2021 15:59

Some right thick people... I mean who'd want to sell these at this time. This is going to double very soon.

[qs99] 02/2/2021 15:56

Hooded Claw, thanks mate and agree. The 1st sales for NCYT started to see it motor as people realised the potential. GDR need to get a few announced as well as other newsflow to continue the share price rise....working cap may also be required later down the line as well depending on how they finance their development.....DYOR, holding on for a fiver defo

[richardp19] 02/2/2021 15:50

Easy take it to 200p

[bunz3] 02/2/2021 15:49

with the amount nt seen to buy seen Today ,how low are they running with available shares

how will they have enough shares if more news released

[bunz3] 02/2/2021 15:41

are they running low with share supply that NT being seen so much

[bunz3] 02/2/2021 15:40

nt to buy again

[andymunchkin] 02/2/2021 15:35

AnyOne knows whoseSellin?

[losses] 02/2/2021 15:30

Definitely can't fathom why these are still under a pound.. will seem like a bargain in the coming weeks when the share price will double from here

[richardp19] 02/2/2021 15:24

Now is the time to buying under 100p. I'm buying in small bits and building a nice position

[bunz3] 02/2/2021 15:22

15,000 share buy or order filled gone through

[hooded claw] 02/2/2021 15:20

QS99, I agree. Putting everything else to one side including the PoC test to be released this quarter I think people are still focusing on "GDR hasn't sold a test" instead of looking at what this deal can do to GDR's market cap.

AVCT is £310m market cap and they are further behind than GDR and their PoC test doesn't work. If GDR had the same market cap it would be £5 a share.

The way things scale up when you work out machines, cost of test, quantity, number of labs, shifts worked then the roll out will be quick and have a huge impact to GDR's revenue.

[bunz3] 02/2/2021 15:16

NT to buy ,such an annoying day

[hooded claw] 02/2/2021 15:12

The MM con is over and back to rising

[qs99] 02/2/2021 15:07

Just think with the massive potential for GDR it is the wrong price currently....DYOR but first sales will show direction of travel .....a good Feb/Mar ahead! Cheers

[hazl] 02/2/2021 14:58

Big pharma is going to make billions.

[maxplus2] 02/2/2021 14:58

So why have they published the rns today and not on December 2020?

[hazl] 02/2/2021 14:49

Thank you HC.

Things looking exciting now!

[richardp19] 02/2/2021 14:45

That's right claw. Think it was a dirty trick but bodes well and back on the rise now. Some of these big investors could even be increasing their holding apart from bgf.

[hooded claw] 02/2/2021 14:43

hazi, no they didn't ... shares in issue rose from 56m to 63m on the 11th December which was when the last of the debt was converted into 6.5m shares so Calculus % holding dropped 1% because of the conversion.

[hazl] 02/2/2021 14:41

Ah was it dilution Richard?


Been working,not caught up.